

GENSET.019A



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#8

Applicant : Dumas Milne Edwards et al.

Appl. No. : 09/215,435

Filed : December 17, 1998

For : EXTENDED CDNAS

Examiner : Unknown

) Group Art Unit 1652

) I hereby certify that this correspondence and all
) marked attachments are being deposited with
) the United States Postal Service as first-class
) mail in an envelope addressed to: Assistant
) Commissioner for Patents, Washington, D.C.
) 20231, on

June 29, 1999

(Date)

Daniel Hart
Daniel Hart, Reg. No. 40,637

LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The Applicants respectfully request that the full last name of the first inventor be used in all communications from the Patent and Trademark Office. Kindly note that the last name of the first named inventor, (Jean-Baptiste Dumas Milne Edwards), is Dumas Milne Edwards. OK.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 29, 1999

By: *Daniel Hart*
Daniel Hart
Registration No. 40,637
Attorney of Record
620 Newport Center Drive, 16th Floor
Newport Beach, CA 92660
(619) 235-8550

S:\DOCS\DOH\DOH-3016.DOC
062999



644-1652/21 PATENT
BOX SEQ
Case Docket No. GENSET.019A
Date: June 29, 1999

W/D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Dumas Milne Edwards et al.
App. No. : 09/215,435
Filed : December 17, 1998
For : EXTENDED CDNAS
Group Art Unit : 1652

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

June 29, 1999

(Date)

Daniel Hart
Daniel Hart, Reg. No. 40,637

TRANSMITTAL LETTER

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RECEIVED

JUL 07 1999

TECH CENTER 1600/2900

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, which was mailed by the Office on January 29, 1999 and May 17, 1999, enclosed are:

- (X) Substitute Sequence Listing in 400 pages.
- (X) Substitute Sequence Listing in computer readable form.
- (X) Sequence Submission Statement in 1 page.
- (X) An extension of time to respond for 4 month(s) is hereby requested.

#6 Ext. of Time (4m)
Goodman
07
09
99

Time Extension Fee:

- (X) Four months (1,360 large entity)
- (X) A Copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, which was mailed by the Office on January 29, 1999.
- (X) A Copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, which was mailed by the Office on May 17, 1999.
- (X) Preliminary Amendment in 1 page.

PATENT

Case Docket No. GENSET.019A

Date: June 29, 1999

RECEIVED

JUL 07 1999

TECH CENTER 1600/2900

- (X) Letter in 1 page.
- (X) Return prepaid postcard.
- (X) Fees as calculated below:


FEE FOR EXTENSION OF TIME (LARGE ENTITY)	4 months	\$ 1,360
SURCHARGE 37 CFR 1.16(e)		\$ + 130
TOTAL FEES SUBMITTED HERewith		\$ 1,490

- (X) A check in the amount of \$1,490 to cover the above fees is enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Daniel Hart

Daniel Hart
Registration No. 40,637
Attorney of Record

GENSET. 01/99
NA/DOH



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIVING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
--------------------	-----------------------	-----------------------	---------------------------

09/215,435 12/17/98 EDWARDS

GENSET 01/99

020995 02127/0129
KNOBBE MARTENS OLSON & BEAR
620 NEWPORT CENTER DRIVE 16TH FLOOR
NEWPORT BEACH CA 92660

NOT ASSIGNED

1442
DATE MAILED:

01/29/99

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. OTHER:

APPLICANT MUST PROVIDE:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- ☐ An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

- ☐ For Rules Interpretation, call (703) 308-1123.
- ☐ For CRF submission help, call (703) 308-4212.
- ☐ For PatentIn software help, call (703) 308-6856.

Customer Service Center
Initial Patent Examination Division (703) 308-1202


PART 2 - COPY TO BE RETURNED WITH RESPONSE

COPY

Application No. **09/215,435**

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE